 Program Description In this CME-Certified presentation, Dr. Michael Atkins will review the use of cytokines for the treatment of advanced renal cell carcinoma. Clinical trials indicate that while most patients do not respond to high-dose IL-2, a small proportion of patients achieve durable complete responses. Efforts to identify predictive factors associated with responses to cytokine therapy are discussed. The module will also review the benefit of adding nephrectomy, and, more recently, targeted agents to enhance the efficacy of cytokine therapy. Target Audience This activity has been designed for community-and hospital-based medical oncologists, hematologists, urologists, nephrologists, and allied healthcare providers who provide medical care and support to patients with renal cell carcinoma. Learning Objectives After completing this program, participants should be able to
Faculty Robert A. Figlin, MD (Activity Director) Arthur and Rosalie Kaplan Chair in Oncology Professor and Chair, Medical Oncology and Therapeutics Research City of Hope National Medical Center and Beckman Research Institute Associate Director for Clinical research City of Hope Comprehensive Cancer Center Duarte, California Michael B. Atkins, MD Deputy Chief, Division of Hematology/Oncology Director of Biologic Therapy and Cutaneous Oncology Programs Director, Cancer Clinical Trials Office Associate Director for Clinical Research Beth Israel Deaconess Medical Center Leader, Kidney Cancer Program Dana-Farber/Harvard Cancer Center Professor of Medicine Harvard Medical School Boston, Massachusetts Accreditation This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the City of Hope and Alliance Medical Communications. The City of Hope is accredited by the ACCME to provide continuing medical education for physicians. Designation of Credit This activity is designated for .5 AMA Physicians’ Recognition Award™ credits. To receive your CME credits you are requested to review the material in full and take the post-test and evaluation. Your evaluation of the activity and comments will remain confidential. Disclosure City of Hope takes responsibility for the content, quality and scientific integrity of this continuing medical education (CME) activity. Prior to their participation in this City of Hope CME activity, all faculty/presenters have disclosed any real or apparent vested commercial interest(s) in both those companies whose products may be discussed during the course of the activity and in those companies acting as commercial supporters of the activity. City of Hope further requires that prior to the activity, faculty/presenters have disclosed their intention to discuss any off-label and/or investigational (not yet approved for any purpose) use of pharmaceuticals or medical devices. Written disclosure of faculty/presenters’ specific commercial relationships and/or intent to discuss off-label and/or investigational is provided below. Robert A. Figlin, MD (Activity Director)
Michael B. Atkins, MD
Dr. Atkins reported the following specific mention of off-label and/or investigational use of products within his presentation.
References
Top of the Page>>  |
